Mutant p53 Co-Crystal Compounds for DNA-Binding Recovery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Cancer cells evade apoptosis through suppression of p53 function, leading to uncontrolled proliferation and metastasis, as p53 mutations destabilize the protein structure and hinder its DNA-binding activity.
Innovation Solution
Compounds that bind to mutant p53 proteins, such as the Y220C mutant, stabilize the protein conformation, forming hydrogen bonds with Thr-150, converting it into a pro-apoptotic form, thereby restoring wild-type p53 activity and enhancing its DNA-binding ability.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If p53 mutations occur, then cancer progression is promoted, but the protein structure becomes destabilized and DNA-binding activity is hindered
Solution Approach 1:
The patent introduces small molecule compounds as intermediary substances that bind to mutant p53 proteins and stabilize their structure. These compounds act as mediators between the mutated protein and its functional state, restoring DNA-binding activity without directly treating the cancer itself. The compounds interfere with the harmful effect of the mutation by providing structural support to the destabilized protein.
Solution Approach 2:
The patent modifies the structural parameters of the p53 protein through chemical binding. By introducing compounds with specific molecular structures (containing hydrogen bond donors and electron-withdrawing heteroatoms), the patent changes the conformational parameters of mutant p53, transforming it from a destabilized state to a stable, functional state that can effectively bind DNA and suppress cancer.
2Reliability
If compounds bind to mutant p53, then protein conformation is stabilized and DNA-binding activity is restored, but the complexity of the treatment system increases
Solution Approach 1:
The patent optimizes the molecular parameters of the compounds to achieve effective binding with minimal structural complexity. By carefully selecting compounds with specific functional groups (hydrogen bond donors proximal to electron-withdrawing heteroatoms), the patent achieves conformational stabilization through relatively simple molecular interactions, avoiding the need for complex multi-component treatment systems.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The compounds increase the DNA-binding capacity and apoptotic activity of mutant p53, potentially inhibiting cancer progression by up to 10,000-fold, inducing apoptosis, cell cycle arrest, or senescence in cancer cells.
Implementation Method 1
the hydrogen bond donor forms a hydrogen bond with Thr-150 of the mutant p53 protein
Data Source
AI summary
Mutations in oncogenes and tumor suppressors contribute to the development and progression of cancer. Disclosed herein are compounds and methods to recover wild-type function of p53 mutants using x-ray co-crystal structures of mutant p53 and compounds of the disclosure. The compounds of the present invention can bind to mutant p53 and restore the ability of the p53 mutant to bind DNA and activate downstream effectors involved in tumor suppression. The disclosed compounds can be used to reduce the progression of cancers that contain a p53 mutation.